MabVax Therapeutics Holdings, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (32)

View All

Latest Posts

About This Stock More About This Stock
With Cash In Hand, Focus For MabVax Turns To The Clinical Program
Article By: Jason Napodano
Monday, May 22, 2017 12:57 PM EDT
This morning, MabVax Therapeutics closed a public offering of $4.1 million in cash. The company offered 1.343 million shares.
In this article: MBVX Also: OPK
Read
MabVax Posters Highlight Why I Like This Story
Article By: Jason Napodano
Thursday, April 6, 2017 1:52 PM EDT
MSKCC continues to be an excellent clinical investigator for MabVax Therapeutics. Cash is perhaps the only missing piece to the story, which I expect management to address in the near future.
In this article: MBVX
Read
Biotech Is Hot But Here’s One Markets Just Missed: MabVax Therapeutics Holdings
Article By: Samuel Rae
Thursday, December 1, 2016 6:29 PM EDT
Here's a look at the latest development in MabVax, and why moving from stage one to stage two in the company's lead trial is so important.
In this article: MBVX Also: PZRX
Read
MabVax Reports Highly Encouraging Phase 1 Data In Pancreatic Cancer
Article By: Jason Napodano
Tuesday, November 15, 2016 3:34 PM EDT
MabVax Therapeutics, Inc. is an incredibly intriguing and undervalued biopharma company. Management is currently examining MVT-5873 and MVT-2163 in a Phase 1 clinical study for the treatment and detection of metastatic pancreatic cancer.
In this article: MBVX
Read
Return On Invested Capital: The Best And Worst
Article By: David Trainer
Monday, April 25, 2016 1:53 PM EDT
ROIC is the best measure of corporate performance and the primary driver of stock prices. We show the companies with the highest and lowest ROIC.
In this article: EDU, TXMD, CRDS, ANTH, AAPL, CHKP, UBNT, VEEV, MBVX, RSPI
Read
All Posts

Latest Tweets for $MBVX

No tweets yet!

PARTNER HEADLINES